Transglutaminase 2 regulates ovarian cancer metastasis by modulating the immune microenvironment.

ABSTRACT:

Introduction

Ovarian cancer is the most lethal gynecological malignancy. Deepening our knowledge of the interactions within the tumor microenvironment (TME) is important for discovering new targeted treatment strategies. Transglutaminase 2 (TG2) is a protein implicated in many biological and pathophysiological processes, including promoting tumor progression in ovarian cancer. Its role in disease progression has been studied in ovarian cancer cells; however, its role in the ovarian TME is less understood.

Methods

In this study, for the first time, we assessed the therapeutic potential of novel covalent irreversible small molecule TG2 inhibitors in xenograft models of ovarian cancer. We further elucidated the role of TG2 in ovarian cancer cells and syngeneic tumors by immune

SUBMITTER: Ibrahim D 

PROVIDER: S-EPMC12328189 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature